AvantGen

What AvantGen does

AvantGen is a privately-held San Diego biotechnology company that operates a contract research and technology licensing business around proprietary yeast display antibody discovery. The company's core asset is the Germliner™ Library Collection, comprising more than 100 billion human antibody clones (reported elsewhere as expanding to 200+ billion) derived from deep sequencing of over 500 individuals, distributed across three display formats: AvantEpee (scFv, 30B clones), AvantSabre (Fab, 100B clones) and AvantFoil (VHH nanobody, 20B clones). These are complemented by AvantGeneer (rational-design affinity maturation using focused CDR mutagenesis and MACS/FACS screening, targeting 10–100x affinity gains), AvantBunny (rabbit monoclonal discovery), and an NK Cell Engager platform with 10,000-fold selectivity for CD16a over CD16b. Platform output is illustrated by sub-nanomolar affinity antibodies delivered against 200+ antigens, and a marketed diagnostic product — the AccuRate™ COVID-19 SelfCheck lateral flow test — developed with NIH RADx support.

The business operates a hybrid B2B model with three revenue streams: (i) fee-for-service antibody discovery and optimization for pharmaceutical, biotechnology and diagnostic companies; (ii) milestone and royalty payments tied to partnered therapeutic programs that have advanced into the clinic (e.g., Adcentrx ADRX-0706 ADC in Phase 1; Kite/Gilead CD19 CAR-T in Phase 1; Tanabe Research Labs cancer program; IGM Biosciences licensed anti-SARS-CoV-2 antibodies); and (iii) non-dilutive grant funding via over 20 NIH SBIR awards and RADx contracts. Pricing is quote-based and not publicly disclosed. Go-to-market is relationship-driven direct sales to enterprise pharma/biotech/diagnostic buyers (Adcentrx, IGM Biosciences, Kite Pharma, Tanabe Research Laboratories) supplemented by SBIR-funded work for NIH/NCI/NIDA and academic collaborators (e.g., Mount Sinai, SISCAPA Assay Technologies). The company is founder-led by Dr. Xiaomin Fan with a small (1–10) San Diego headcount and has not disclosed venture financing.

Name

AvantGen

Legal name

AvantGen Inc.

Website

https://avantgen.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

AvantGen is a privately-held San Diego biotechnology company that uses proprietary yeast display technology and the Germliner™ human antibody library collection to discover, optimize and license therapeutic and diagnostic antibodies for pharmaceutical, biotechnology and diagnostic companies, as well as NIH-funded research partners.

Ownership category

akta.pro rank

Product category

Antibody Discovery and Engineering Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Antibody discovery services
• Yeast display technology
• Therapeutic antibody engineering
• Bispecific antibody platforms
• Monoclonal antibody optimization

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services: Fee-for-service antibody discovery and optimization services. AvantGen generates novel antibodies to specified targets using proprietary platforms for pharmaceutical, biotech, and diagnostic partners. Receives upfront payments for project initiation.
2. Milestone Payments: Payments triggered by achievement of specific development milestones such as IND clearance, clinical trial enrollment, and regulatory approvals. Common in therapeutic antibody partnerships.
3. Royalty Payments: Ongoing royalty payments based on development and sale of any products derived from collaborations. AvantGen receives royalties associated with the development and sale of licensed products.
4. Technology Licensing: Licensing of proprietary antibody clones and platform technologies to biotechnology and pharmaceutical companies for specific therapeutic or diagnostic applications.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

AvantGen provides antibody discovery and optimization services to pharmaceutical, biotechnology, and diagnostic companies using proprietary yeast display technology. The company leverages its Germliner™ Library Collection of over 100 billion fully human antibody clones to deliver scFv (AvantEpee), Fab (AvantSabre), and VHH nanobody (AvantFoil) hits, complemented by affinity maturation (AvantGeneer), rabbit monoclonal discovery (AvantBunny), and bispecific NK cell engager platforms. Revenue is generated through fee-for-service contracts, milestone payments, royalties, and platform technology licensing.

Product overview

AvantGen offers an integrated suite of antibody discovery and engineering platforms built on proprietary yeast display technology. The core Germliner™ Library Collection comprises over 100 billion fully human antibody clones displayed on yeast. The three primary discovery platforms are AvantEpee (scFv, 30 billion clones), AvantSabre (Fab, 100 billion clones), and AvantFoil (VHH nanobodies, 20 billion clones). These are complemented by AvantGeneer for affinity maturation and optimization, AvantBunny for rabbit monoclonal antibody generation, and an NK Cell Engager platform for cancer immunotherapy. The company also developed the AccuRate™ COVID-19 SelfCheck diagnostic product. Platforms support therapeutic, diagnostic, and research tool applications.

Differentiator

Problem solved

Functional benefit

Brands

• AvantEpee: Single-chain Fv (scFv) antibody discovery platform with 30 billion clones
• AvantSabre
• AvantFoil
• AvantGeneer
• AvantBunny
• AccuRate

Products and services

• AvantEpee (scFv Antibody Library) Yeast-displayed single-chain Fv (scFv) antibody discovery platform with 30 billion pre-made human antibody clones, designed for scFv, bispecifics, and CAR-T/NK therapeutic modalities. Available as a service to pharmaceutical and biotechnology partners.
• AvantSabre (Fab Antibody Library) Yeast-displayed Fab antibody library platform with 100 billion pre-made human clones, ideal for antibody therapeutics in Fab or whole antibody format. Available as a service to pharmaceutical, biotechnology, and diagnostic partners.
• AvantFoil (VHH Antibody Library) Yeast-displayed VHH (heavy chain only) nanobody antibody discovery platform with 20 billion clones. VHHs offer faster diffusion properties and ability to target hard-to-reach epitopes. Available as a service to therapeutic and diagnostic partners.
• AvantGeneer (Antibody Engineering) Antibody optimization platform providing affinity maturation, specificity improvement, species cross-reactivity adjustment, pH dependency modification, and liability removal. Uses rational design of focused libraries with point mutations across all 6 CDRs (>10^9 clones) and rapid MACS/FACS screening for 10- to 100-fold affinity improvement. Service offered to partners with existing antibody leads.
• AvantBunny (Rabbit Monoclonal Antibody Discovery) Rabbit monoclonal antibody discovery platform combining optimized rabbit immunization protocol with robust yeast display system. Rabbit antibodies deliver 10-100 fold higher affinity than mouse monoclonal antibodies and can distinguish subtle structural variations. Service offered for critical reagent and diagnostic antibody discovery.
• NK Cell Engager Platform Bispecific NK cell engaging therapeutic antibody platform generating antibodies targeting CD16a on NK cells. Demonstrates 10,000-fold selectivity over CD16b, higher NK cell recruitment and tumor cell killing, increased thermostability, and unabated function in presence of serum. Available for licensing to biopharmaceutical companies for cancer immunotherapy development.
• AccuRate™ COVID-19 SelfCheck Over-the-counter lateral flow rapid antigen test using ultra-performing high affinity monoclonal antibodies against SARS-CoV-2 nucleocapsid protein. Demonstrates Limit of Detection of 70 TCID50/mL, outperforming many EUA OTC tests, with 100% sensitivity in detecting N protein in clinical samples (n=55; Ct values 14-38).
• Therapeutic Antibody Discovery Services Fee-for-service antibody discovery and optimization for pharmaceutical, biotechnology, and diagnostic companies. AvantGen generates novel antibodies to specified targets using proprietary yeast display platforms. Service includes upfront payments for project initiation, milestone payments on development progress, and royalties on licensed products. Successfully fulfilled hundreds of projects.

Quantifiable outcome

• 10-100 fold affinity improvement through AvantGeneer optimization
• +5 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Five partnerships are on record, tiered core, major and minor.

• Adcentrx TherapeuticscoreStrategic or Co-development Partner · 14 February 2022Three-year, multi-target partnership for antibody discovery to be developed into novel antibody-drug conjugate (ADC) therapeutic candidates. AvantGen screens for novel antibodies using its yeast display system; Adcentrx engineers antibodies into ADC candidates and has worldwide development and commercialization rights. AvantGen eligible for milestone payments. Partnership resulted in ADRX-0706 which received FDA IND clearance and first patient dosing in Phase 1 trial.
• Undisclosed Biopharmaceutical CompanymajorStrategic or Co-development Partner · 7 November 2019Strategic collaboration agreement to generate multiple novel bi-specific NK cell engaging therapeutic antibody product candidates. AvantGen responsible for engineering bi-specific variants using proprietary NK cell engager platform and partner's antibodies against novel disease target. Partner receives worldwide exclusive rights. AvantGen receives upfront, milestone, and royalty payments.
• Tanabe Research Laboratories USA, Inc. (TRL)majorStrategic or Co-development Partner · 4 January 2018Expanded collaboration for therapeutic antibody discovery. AvantGen responsible for generating novel antibodies to specified cancer targets using proprietary human antibody yeast display technology. TRL has worldwide rights to develop and commercialize antibodies. AvantGen receives upfront payments and is eligible for milestone payments and royalties. This was the fifteenth de novo antibody discovery project initiated for corporate partners.
• SISCAPA Assay TechnologiesminorStrategic or Co-development Partner · 18 September 2015Collaboration on NIH/NCI SBIR Phase II contract to develop high-affinity anti-peptide rabbit monoclonal antibodies for SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) assays for cancer biomarker detection.
• Mount Sinai Icahn School of MedicineminorStrategic or Co-development Partner · 1 March 2015Collaborator on NIH/NIDA SBIR Phase II grant for development of rabbit monoclonal neuroscience antibodies against challenging targets. Antibodies to be fully characterized by Mount Sinai.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• GenScript ProBio: Large CDMO/CRO arm of GenScript offering antibody discovery, engineering, and manufacturing services including single B-cell screening and humanization. Comparable as a fee-for-service antibody discovery provider for biotech/pharma, though much broader in scope and scale than AvantGen.
• Ligand Pharmaceuticals: Biopharmaceutical company with antibody and protein technology platforms (OmniAb, Captisol) generating royalty streams from licensed programs. Comparable revenue model (royalty/milestone-driven) and platform licensing approach, though at much larger scale and broader therapeutic footprint.
• WuXi Biologics: Global biologics CRO/CDMO offering antibody discovery, cell line development, and GMP manufacturing services for pharma and biotech. Overlaps with AvantGen in early-stage antibody discovery, but with vastly greater scale, geographic reach, and integrated discovery-to-manufacturing offering.
• BioLegend (Revvity): Major provider of antibody and reagent products for life science research, now part of Revvity. Comparable in antibody engineering and rabbit monoclonal capabilities (LEGENDplex, Ultra-LEAF), though focused on catalog reagent products rather than therapeutic discovery partnerships.

Direct peers

• Adagene: Clinical-stage biotech using proprietary antibody discovery and engineering platforms (Powerful Screening, NEObody, SAFEbody) to develop therapeutic antibodies internally and via partnerships. Comparable as an antibody platform company combining proprietary libraries with optimization and licensing of assets to larger partners.
• AbCellera Biologics: Vancouver-based antibody discovery platform company leveraging a proprietary library (>50B clones) and single-cell screening to discover therapeutic antibodies for partners. Directly competes with AvantGen in yeast/display-based antibody discovery for pharma/biotech partners, with similar fee-for-service + milestone/royalty economics.
• AnaptysBio: Clinical-stage antibody development company with proprietary somatic hypermutation-based discovery platform generating wholly-owned and partnered antibodies. Comparable as a platform antibody company that licenses programs to pharma and earns milestones/royalties, with emphasis on IL-36R, PD-1 agonists, and immuno-oncology.
• Absolute Antibody: UK-based antibody services and recombinant antibody expression company offering antibody sequencing, engineering, and recombinant production services. Comparable as a specialist CRO providing antibody engineering, humanization, and recombinant production for pharma/biotech clients.
• Distributed Bio (acquired by Charles River Laboratories): Was an independent antibody discovery CRO with proprietary SuperHuman and AbGenesis libraries, now part of Charles River's Discovery and Safety Solutions. Provides near-direct overlap with AvantGen's fully human antibody library discovery service offering for pharma and biotech clients.

Emerging players

• Atreca: Clinical-stage antibody therapeutics company using immune repertoire sequencing and screening to discover natively-paired antibodies from vaccinated or immunized donors. Comparable technology overlap with AvantGen's deep-sequencing approach (Germliner), though Atreca is more internally pipeline-focused than CRO/services-oriented.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Customer concentration

• LinkedInlinkedin.com/company/avantgen-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AvantGen